Loading
Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval.
Ian Krop (Yale Cancer Center) led the early development of trastuzumab emtansine including its phase 1 and TH3RESA trials, and was a lead investigator of the DESTINY-Breast programme that made trastuzumab deruxtecan standard second-line therapy for HER2-positive disease. He chairs the Translational Breast Cancer Research Consortium and leads early-phase ADC trials.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc, her2.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares DESTINY-Breast03, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab emtansine, Trastuzumab deruxtecan.
Shares DESTINY-Breast03, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab emtansine, Trastuzumab deruxtecan.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).